A Facile Synthesis of Amide Derivatives of [1,2,4]Triazolo[4,3-a]pyridine

N. MURTHY GANDIKOTA¹, R. SEKHAR BOLLA¹, I.V. KASI VISWANATH^{1,*} and SRIDHARREDDY BETHI²

¹Department of Chemistry, K.L. University, Green Fields, Vaddeswaram, Guntur-522 502, India

²G.V.K. Bio Sciences, Hyderabad, India

*Corresponding author: E-mail: viswanath_fed@kluniversity.in

Received: 4 March 2017;

Accepted: 12 May 2017;

Published online: 15 July 2017;

AJC-18466

A facile synthesis for preparation of amide derivatives of [1,2,4]triazolo[4,3-a]pyridine can be achieved by the nucleophilic displacement of chloromethyl derivative with methyl amine followed by the reaction with acid analogues in the presence of 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU). Reaction of 2-chloropyridine with hydrazine hydrate (99 %) gave 2-hydrazinopyridine (**2**). Compound **3** was obtained in good yields by treating 2-hydrazinopyridine with chloroacetyl chloride. Further 3-chloromethyl-[1,2,4]triazolo[4,3-a]pyridine (**4**) is obtained by treatment of compound **3** with POCl₃. Nucleophilic displacement of compound **4** with methyl amine gave methyl-[1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl-amine (**5**). Finally protecting and deprotecting of compound **5** with Boc anhydride and HCl in dioxane gives hydrochloride salt of compound **5** i.e. (**6**). The reaction of hydrochloride salt of methyl-[1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl-amine with 10 different acids yields amide analogues.

Keywords: *s*-Triazolo pyridines, Pyridine derivatives, 1,2,4-Triazolo[4,3-a]pyridine, Triazolo derivatives.

INTRODUCTION

Pyrolo, imidazo- and triazolo pyridines belonging to class of N-bridge head 5,6-bicyclic heterocycles are important motifs in bio-medicinal chemistry due to their good SAR (structure-activity relationship). Among them *s*-triazolo(4,3-a)pyridine ring system (**I**) that has been known since several years but to which meager attention has been paid. An effort was initiated to develop the synthesis amido aminomethyl fused triazoles (**II**) that would be compatible with amino acid substrates and polar functional groups.

A wide range of research was going on these derivatives because of their interesting biological activities like anti-microbial [1], antiviral [1], anticonvulsant [1], antifungal [1], anticancer [1], antiallergic [2], herbicide activity [3], anti-oxidants [1]. These fused triazoles with general formula **I** are specially shows gastrointestinal [4] and chemotherapeutic activity [4-6] due to their outstanding effectiveness against a wide range of micro-organisms, such as, *Staphylococcus aureus*, *Escherichia coli*, *Proteus mirabilis*, *Pseudomonas aeruginosa* and *Streptococcus pyogenes*. These derivatives are used in the treatment of schistosomiasis [7] a typical disease found in Egypt. These 1,2,4-triazolo[4,3-a]pyridine derivatives have a considerable effect on glutamate [8,9]. This helps us to cure neurological and psychiatric disorders, which are associated with glutamate dysfunction. Triazolopyridines are found in

MAP kinase inhibitors [10-12] and secretagogues, which is a growth hormone. There are reports on some classes of 1,2,4-triazolo[4,3-a]pyridine derivatives can be used as p38 α inhibitors [10-13]. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders. Some biologically active molecules containing [1,2,4]triazolo[4,3-a]pyridine as a core moiety are represented in Fig. 1.

There are several methods for the preparation of amino methyl derivatives. Decarboxylation of α -heteroaryl glycines, reduction of methyl azides, nitriles and aldoximes are some of them. To the best of our knowledge there are few reports available for the synthesis of amino methyl substituted 1,2,4-triazolo[4,3-a]pyridine, especially on our target molecule methyl[1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl-amine (**V**).

Several synthetic approaches were known for the synthesis of 3-chloromethyl-[1,2,4]triazolo[4,3-a]pyridine (**III**) [4] and [1,2,4]triazolo[4,3-a]pyridin-3-yl-ethylamine (**IV**) [14] and fewer number of synthetic approaches are known for methyl-[1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl-amine (**V**) and ours is a novel approach. But amide derivatives of **V** were not reported yet. Intermediate **5** may be prepared by Mitsunobu reaction [15]. This reaction can be carried out in the presence of triphenyl phosphine, diethyl azodicarboxylate (DEAD) and TMS cyanide as an additive. But this procedure is complicated and involves hazardous reagent TMS cyanide. We synthesized

Fig. 1. Biologically active molecules containing [1,2,4]triazolo[4,3-a]pyridine as a core moiety

methyl-[1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl-amine (**V**) in an economical way by using 2 M methyl amine/THF. After preparing compound **7** we planned a methodology, which involves acid amine coupling. In this methodology we will get compounds with chemical formula **II**.

Bearing these results in mind, we have designed and synthesized a new variety of amide derivatives of [1,2,4]triazolo[4,3-a]pyridine.

Due to their high structure activity relationship values N-(heteroaryl)methyl aromatic amides fall under an important class of bioactive compounds [16] *i.e.* amino methyl derivatives containing pyridine, thiophene, pyrazene and other heterocyclic systems possess high potency of biological activity.

EXPERIMENTAL

Fig. 2 depicts the synthetic route for the preparation of hydrochloride salt of methyl-[1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl-amine (**7**). 2-Chloro pyridine was treated with hydrazine hydrate (99 %) at 100 °C for 48 h to yield hydrazine derivative of pyridine (**2**) [2,5,7,9,17,18]. Compound **2** was selectively mono acylated with chloroacetyl chloride to afford amide derivative (**3**) of compound **2** [2,9,17,18]. Further, compound **3** was cyclized with POCl_3 with the elimination of water molecule to afford 3-chloromethyl-[1,2,4]triazolo[4,3-a]-

pyridine (**4**) [4,17]. Further, compound **4** is converted to methyl-[1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl-amine (**5**) by treating with 2 M methyl-amine in methanol. As compound **5** was unable to purify at that stage hence it was protected with $(\text{Boc})_2\text{O}$ to give methyl-[1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl-carbamic acid *tert*-butyl ester (**6**). Finally, compound **6** was deprotected with HCl/dioxane to afford hydrochloride salt of methyl-[1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl-amine (**7**).

Fig. 3 illustrates the synthesis of amide derivative of methyl-[1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl-amine (**7**). In this reaction we used 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU) as a peptide coupling reagent and *N,N*-diisopropylethylamine (DIPEA) as a base in DMF solvent. A series of amide derivatives were prepared by using above condition with good yields and purity.

Fig. 3. Synthesis of N-(heteroaryl)methyl aromatic amide

All reagents were purchased from commercial sources and were used as received. ^1H NMR spectra were obtained on a AGILENT 300 spectrometer at 300 MHz or AGILENT 400 spectrometer at 400 MHz with tetramethylsilane used as an internal reference. Thin-layer chromatography (TLC) was performed using Whatman No. 4500-101 (Diamond No. MK6F silica-gel 60 Å) plates. Visualization of TLC plates was performed using UV light (254 nm). LCMS was obtained on the Column: X Bridge C18 (100 mm $\times$ 4.6 mm) 3.5 μm .

Synthesis of pyridin-2-yl-hydrazine (2**):** To a stirred solution of **1** (20 g, 0.176 mol, 1 equiv) in hydrazine hydrate (200 mL, 10 vol) was stirred at 100 °C for 48 h. When TLC (8:2 EtOAc and methanol) showed complete consumption of the starting material, the reaction mixture was diluted with water (200 mL) and extracted with ethyl acetate (5 $\times$ 500 mL), dried over Na_2SO_4 evaporated to dryness under reduced pressure to afford **2** (15.0 g, 78 %) as a red oil; ^1H NMR (300 MHz, CDCl_3): δ 8.14 (1H, d, J = 3 Hz, Ar-H), 7.51-7.45 (1H, m, Ar-H), 6.71-6.66 (2H, m, Ar-H), 5.78 (1H, brs, -NH), 3.81 (2H, brs, $-\text{NH}_2$); LCMS calculated for $\text{C}_5\text{H}_7\text{N}_3$: 109.13; Found 110.1, $[\text{M}+\text{H}]^+$

Fig. 2. Synthesis of hydrochloride salt of methyl-[1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl-amine

Synthesis of chloro-acetic acid N'-pyridin-2-yl-hydrazide

(3): To a stirred solution of compound **2** (5 g, 1 equiv) in dichloromethane (100 mL) was added chloroacetyl chloride (4.19 mL, 1.1 equiv) drop wise at 0 °C with vigorous stirring. After completion of addition formation of white precipitate was observed, this was stirred at ambient temperature for 12 h. When TLC (9:1 EtOAc and methanol) showed complete consumption of the starting material, the reaction mixture was filtered and the obtained solids were washed with dichloromethane (30 mL), solids were dissolved in water (50 mL) and basified (pH 8.0) with sat. NaHCO₃ and extracted with dichloromethane (3 × 100 mL), dried over Na₂SO₄, evaporated under reduced pressure to afford compound **3** (5.00 g, 58 %) as a white solid; ¹H NMR (300 MHz, DMSO-*d*₆): δ 10.87 (1H, brs, -NH), 10.59 (1H, brs, -NH), 8.07-8.00 (2H, m, Ar-H), 7.13-7.03 (2H, m, Ar-H), 4.3 (2H, s, -CH₂Cl); LCMS calculated for C₇H₈N₃OCl: 185.61; Found 186 [M+H]⁺.

Synthesis of 3-chloromethyl-[1,2,4]triazolo[4,3-a]pyridine (4): Under inert atmosphere POCl₃ (25 mL, 5 vol) was slowly added to compound **3** (5 g, 0.027 mol) at ambient temperature, the resulting reaction mixture was stirred at 120 °C for 12 h. Reaction was monitored by TLC (9:1 EtOAc/methanol), which showed complete consumption of the starting material, POCl₃ was evaporated completely, the crude was basified with sat. NaHCO₃. The aqueous layer was extracted with dichloromethane (3 × 100 mL). The combined organic layers were dried over Na₂SO₄, evaporated under reduced pressure to afford crude product. The crude was triturated with ether to afford compound **4** (2.5 g, 55.55 %) as a brown solid. ¹H NMR (400 MHz, CDCl₃): δ 8.19 (1H, d, *J* = 8 Hz, Ar-H), 7.84 (1H, d, *J* = 8 Hz, Ar-H), 7.39-7.34 (1H, m, Ar-H), 7.00-6.97 (1H, m, Ar-H), 5.18 (2H, s, -CH₂Cl). LCMS calculated for C₇H₆N₃Cl: 167.60; Found 168.08, 170.08, [M], [M+2]⁺.

Synthesis of methyl-[1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl-amine (5): To a stirred solution of compound **4** (2.50 g, 1.0 equiv) in MeOH (20 mL), was added 2 M solution of methyl amine in methanol (3 mL) at ambient temperature. The reaction mixture was stirred at the same temperature for 12 h. Reaction was monitored by TLC (9:1 EtOAc and methanol) which showed complete consumption of the starting material, the reaction mixture was evaporated under reduced pressure, dried completely to give crude compound **5** (2.3 g) as a red liquid.

Synthesis of methyl-[1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl-carbamic acid tert-butyl ester (6): To a stirred solution of compound **5** (2.30 g, 1.0 equiv) in THF (20 mL) was added Boc anhydride (3.85 mL, 1.1 equiv) at ambient temperature. The reaction mixture was stirred at the same temperature for 12 h. Reaction was monitored by TLC (8:2 EtOAc and methanol) which showed complete consumption of the starting material, the reaction mixture was evaporated, obtained crude was dissolved in water (20 mL). The aqueous layer was initially extracted with pet. Ether (2 × 20 mL) to remove excess Boc anhydride. Further the aqueous layer was extracted with dichloromethane (3 × 20 mL). The combined organic layers were dried over Na₂SO₄, evaporated under reduced pressure to afford crude product. The crude was triturated with ether to afford **6** (2.0 g, 54.0 %) as a brown solid. ¹H NMR (400 MHz, CDCl₃): δ 8.54 (1H, brs, -NH-Boc), 7.77 (1H, d, *J* = 12 Hz,

Ar-H), 7.29 (1H, d, *J* = 8 Hz, Ar-H), 6.86 (1H, t, *J* = 6 Hz, Ar-H), 5.02 (2H, s, -NCH₂), 2.65 (3H, -s, -NCH₃), 1.49 (9H, s, *t*-Bu) MS, LCMS calculated for C₁₃H₁₈N₄O₂: 262.31; Found 263.19 [M + H]⁺.

Synthesis of hydrochloride salt of methyl-[1,2,4]triazolo[4,3-a]pyridin-3-ylmethylamine (7): To a stirred solution of compound **6** (2 g, 1 equiv) in dioxane (10 mL) was added 2 M HCl in dioxane (10 mL) at ambient temperature. The reaction mixture was stirred at the same temperature for 12 h. Reaction was monitored by TLC (8:2 EtOAc and methanol) which showed complete consumption of the starting material, the reaction mixture was evaporated under reduced pressure to dryness and the obtained crude was triturated with ether to afford compound **7** (1.3 g, 86 %) as brown solid. ¹H NMR (300 MHz, DMSO-*d*₆): δ 9.61 (2H, brs, -NHHCl), 8.80 (1H, d, *J* = 6.4, Ar-H), 7.89 (1H, d, *J* = 9.2, Ar-H), 7.56-7.53 (1H, t, *J* = 6.8, Ar-H), 7.18-7.15 (1H, t, *J* = 6.4, Ar-H), 4.79 (2H, s, -NCH₂), 2.70 (3H, s, -NCH₃); LCMS calculated for C₈H₁₁N₄Cl: 162.14; Found 163.21 [M + H]⁺.

General synthetic procedure for synthesis of amide derivatives of methyl-[1,2,4]triazolo[4,3-a]pyridin-3-ylmethylamine (8a-8k): To a stirred solution of compound **7** (100 mg, 1.0 equiv) in DMF (3 mL) was added 4-bromo-2-methyl-benzoic acid (241.32 mg, 1.1 equiv). To this mixture DIPEA (0.526 mL, 3.0 equiv) followed by HATU (387.84 mg, 1.0 equiv) were added at ambient temperature. The reaction mixture was stirred at the same temperature for 2 h. Reaction was monitored by TLC (8:2 EtOAc and methanol), which showed complete consumption of the starting material. The reaction mixture was basified with sat. NaHCO₃. The aqueous layer was extracted with dichloromethane (3 × 100 mL). The combined organic layers were washed with brine, dried over Na₂SO₄ and evaporated under reduced pressure to afford crude product. The crude was purified by silica-gel (100-200) column chromatography using 5 % methanol/ethylacetate as an eluent to afford 4-bromo-2,N-dimethyl-N-[1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl benzamide (**8a**) (30 mg, 70 %) as a off-white solid. Same procedure was adopted for the synthesis of remaining compounds **8b-8k**.

Spectral data

4-Bromo-N-dimethyl-N-[1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl-benzamide (8a): Yield 38 %, Off-white solid. ¹H NMR (400 MHz, CDCl₃, ppm): δ 8.74 (1H, d, *J* = 8 Hz, Ar-H), 7.82 (1H, d, *J* = 6 Hz, Ar-H), 7.39-7.36 (3H, m, Ar-H), 7.19 (1H, d, *J* = 6 Hz, Ar-H), 6.94 (1H, t, *J* = 8 Hz, Ar-H), 5.31 (2H, s, N-CH₂), 2.88 (3H, s, N-CH₃), 2.13 (3H, s, Ar-CH₃); LCMS calculated for C₁₆H₁₅N₄OBr: 359.22; Found 361.08 [M + 2]⁺.

4-Methoxy-N-methyl-N-[1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl-benzamide (8b): Yield 33 %, Off-brown solid. ¹H NMR ((300 MHz, CDCl₃, ppm): δ 8.76 (1H, d, *J* = 6 Hz, Ar-H), 7.79 (1H, d, *J* = 9 Hz, Ar-H), 7.29-7.25 (3H, m, Ar-H), 6.93-6.91 (3H, m, Ar-H), 5.30 (2H, s, N-CH₂), 3.82 (3H, s, O-CH₃), 3.05 (3H, s, N-CH₃); LCMS calculated for C₁₆H₁₆N₄O₂: 296.32; Found 297.21 [M + 1]⁺.

4-N-Dimethyl-N-[1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl-benzamide (8c): Yield 34 %, red gummy solid. ¹H

NMR ((300 MHz, CDCl₃, ppm): δ 8.76 (1H, d, J = 6, Ar-H), 7.79 (1H, d, J = 9.3, Ar-H), 7.33-7.31 (3H, m, Ar-H), 7.21-7.18 (2H, m, Ar-H), 6.91-6.87 (1H, t, J = 6.6, Ar-H), 5.30 (2H, s, N-CH₂), 3.05 (3H, s, N-CH₃), 2.37 (3H, s, Ar-CH₃); LCMS calculated for C₁₆H₁₆N₄O: 280.32; Found 281.18 [M + 1]⁺.

3-Mercapto-N-methyl-N-[1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl benzamide (8d): Yield 30 %, brown gummy liquid. ¹H NMR (400 MHz, DMSO-*d*₆, ppm): δ 8.51 (1H, s, Ar-H), 7.92 (1H, d, J = 12 Hz, Ar-H), 7.56-7.35 (6H, m, Ar-H), 7.04 (1H, s, Ar-H), 5.17 (2H, s, N-CH₂), 2.84 (4H, s, N-CH₃, SH); LCMS calculated for C₁₅H₁₄N₄OS: 298.09; Found 298.22 [M]⁺.

4-Bromo-2-fluoro-N-methyl-N-[1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl benzamide (8e): Yield 22 %, white solid. ¹H NMR (300 MHz, CDCl₃): δ 8.61 (1H, d, J = 6 Hz, Ar-H), 7.80 (1H, d, J = 9 Hz, Ar-H), 7.39-7.29 (3H, m, Ar-H), 7.28-7.21 (1H, m, Ar-H), 6.09 (1H, t, J = 9, Ar-H), 5.32 (2H, s, N-CH₂), 2.95 (3H, s, N-CH₃); LCMS calculated for C₁₅H₁₂N₄OBrF: 363.18; Found 363.22, 365.20, [M], [M + 2]⁺.

2,N-Dimethyl-N-[1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl isonicotinamide (8f): Yield 28 %, Off-white solid. ¹H NMR (300 MHz, CDCl₃): δ 8.69 (1H, d, J = 6 Hz, Ar-H), 8.58 (1H, d, J = 6 Hz, Ar-H), 7.81 (1H, d, J = 9 Hz, Ar-H), 7.36-7.30 (1H, m, Ar-H), 7.12 (1H, s, Ar-H), 7.06 (1H, d, J = 4.2 Hz, Ar-H), 6.95-6.91 (1H, t, J = 6 Hz, Ar-H), 5.29 (2H, s, N-CH₂), 3.03 (3H, s, N-CH₃), 2.58 (3H, s, Ar-CH₃); LCMS calculated for C₁₅H₁₅N₅O: 281.31; Found 282.20 [M + H]⁺.

4-Formyl-3-hydroxy-N-methyl-N-[1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl benzamide (8g): Yield 38 %, Brown solid. ¹H NMR (400 MHz, CDCl₃, ppm): δ 10.87 (1H, s, -CHO), 10.29 (1H, s, -OH), 8.55 (1H, d, J = 4 Hz, Ar-H), 7.81-7.70 (2H, dd, J 1 = 8 Hz, J 2 = 8 Hz, Ar-H), 7.42 (1H, d, J = 8 Hz, Ar-H), 7.08-6.95 (3H, m, Ar-H), 5.21 (2H, s, -N-CH₂), 2.92 (3H, s, -NCH₃); LCMS calculated for C₁₆H₁₄N₄O₃: 310.31; Found 311.15 [M + H]⁺.

3-Chloro-N-methyl-2-nitro-N-[1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl benzamide (8h): Yield 40 %, White solid. ¹H NMR (400 MHz, CDCl₃, ppm): δ 8.63 (1H, d, J = 7.2 Hz, Ar-H), 8.17 (1H, d, J = 8.8 Hz, Ar-H), 7.80 (1H, d, J = 9.2 Hz, Ar-H), 7.57-7.54 (1H, dd, J 1 = 4 Hz, J 2 = 8 Hz, Ar-H), 7.40 (1H, d, J = 4 Hz, Ar-H), 7.36-7.34 (1H, m, Ar-H), 6.94-6.91 (1H, t, J = 4 Hz, Ar-H), 5.39 (2H, s, -NCH₂), 2.82 (3H, s, -NCH₃).

4-Fluoro-3,N-dimethyl-N-[1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl benzamide (8i): Yield 53 %, Off-white solid. ¹H NMR (300 MHz, CDCl₃, ppm): δ 8.76 (1H, d, J = 6.4 Hz, Ar-H), 7.79 (1H, d, J = 8.0 Hz, Ar-H), 7.36-7.33 (3H, m, Ar-H), 7.02 (1H, d, J = 9 Hz, Ar-H), 6.95 (1H, d, J = 7.2 Hz, Ar-H), 5.30 (2H, s, -NCH₂), 3.05 (3H, s, -NCH₃), 2.25 (3H, s, Ar-CH₃); LCMS calculated for C₁₆H₁₅N₄OF: 298.31; Found 299.24 [M + H]⁺.

2-Bromo-N-methyl-N-[1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl benzamide (8j): Yield 40 %, Off-white solid. ¹H NMR (300 MHz, CDCl₃, ppm): δ 8.74 (1H, d, J = 9 Hz, Ar-H), 7.79 (1H, d, J = 9 Hz, Ar-H), 7.56-7.53 (1H, dd, J 1 = 1.2 Hz, J 2 = 6 Hz, Ar-H), 7.40-7.24 (4H, m, Ar-H), 6.58 (1H, brs, -NCH), 5.10 (1H, brs, -NCH), 2.79 (3H, s, -NCH₃); ¹³C NMR

(400 MHz, DMSO-*d*₆, ppm): δ 168.54 (-NC=O), 149.68 (Ar-C), 142.87 (Ar-C), 137.44 (Ar-C), 132.53 (Ar-C), 130.85 (Ar-C), 127.95 (Ar-C), 124.48 (Ar-C), 117.96 (Ar-C), 115.21 (Ar-C), 113.56 (Ar-C), 40.12 (-NCH₂), 35.45 (-NCH₃); LCMS calculated for C₁₅H₁₃N₄OBr: 345.19; Found 344.99, 346.88, [M], [M + 2]⁺.

4-Bromo-3-fluoro-N-methyl-N-[1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl benzamide (8k): Yield 43 %, Off-white solid. ¹H NMR (300 MHz, CDCl₃): δ 8.69 (d, 1H, J = 6 Hz, Ar-H), 7.80 (d, 1H, J = 9 Hz, Ar-H), 7.63-7.58 (m, 1H, Ar-H), 7.35-7.29 (1H, m, Ar-H), 7.20 (1H, d, J = 9 Hz, Ar-H), 7.09 (1H, d, J = 8.1 Hz, Ar-H), 6.93-6.89 (1H, m, Ar-H), 5.27 (2H, s, -NCH₂), 3.08 (3H, s, -NCH₃); ¹³C NMR (400 MHz, DMSO-*d*₆, ppm): δ 169.49 (-NC=O), 159.11 (Ar-C), 156.66 (Ar-C), 149.51 (Ar-C), 142.96 (Ar-C), 133.76 (Ar-C), 128.02 (Ar-C), 124.73 (Ar-C), 115.69 (Ar-C), 113.76 (Ar-C), 109.77 (Ar-C), 40.10

TABLE-1
PHYSICAL DATA OF COMPOUNDS 8a-8k

Compd.	Acid	Product	Time (h)
8a			2
8b			2
8c			2
8d			2
8e			2
8f			2
8g			2
8h			2
8i			2
8j			2
8k			2

(-NCH₂), 36.90 (-NCH₃); LCMS calculated for C₁₅H₁₂N₄OBrF: 363.18 Found 363.22, 365.20, [M], [M + 2]⁺.

RESULTS AND DISCUSSION

The key step in present research is the replacement of chloro with methyl amine. It was assumed to be nucleophilic substitution of order 2. The methyl amine replaces the chloro in a concerted mechanism *i.e.* while the methyl amine attacks the electron deficient carbon, at the same time chloro leaves the carbon. Because of the high polarity and solubility issues obtained amine was protected with Boc anhydride to purify, later de protected to get hydrochloride salt of that amine.

Hydrochloride salt of methyl-[1,2,4]triazolo[4,3-a]pyridin-3-ylmethyl-amine (**7**) was treated with various acid derivatives in the presence of DIPEA and HATU in DMF at ambient temperature to afford the amide derivatives **8a-8k**. This method has the advantages of easier work-up, mild reaction conditions.

The amidic products were confirmed by NMR, mass and ¹³C NMR spectral techniques. In the 300 MHz ¹H NMR spectra of derivatives **8j**, **8k** (in CDCl₃), the following signals were detected. Peaks at δ 8.74-6.89 for aromatic protons, singlet's at δ 6.58-5.24 corresponds to -NCH₂ protons and a singlet at δ 2.78-3.08 represent -NCH₃ protons. In ¹³C NMR (400 MHz, DMSO-*d*₆, ppm), the following signals were detected. A peak at δ 168.54-168.49 corresponds to C=O of amide and a peak at δ 36.90-35.45 corresponds to -NCH₃ carbon. A peak at δ 40 corresponds to -NCH₂ carbon. A series of peaks from δ 159.11-109.56 represents aromatic carbons. Besides NMR studies, mass spectra displayed the exact molecular ion peaks in positive mode. The yields and physical data of the final compounds are given in Table-1.

Conclusion

The present study involves the synthesis of the novel series of [1,2,4]triazolo[4,3-a]pyridine derivatives by adopting a simple and versatile synthetic methodology. From the previous results, we are expecting our newly designed molecules may be biologically active. Thus, this novel class of amide derivatives of [1,2,4]triazolo[4,3-a]pyridine core represents the worthy hit compounds, which can be a basis for further investigations and development of novel potent agents.

REFERENCES

1. R. Singh and A. Chouhan, *World J. Pharm. Pharm. Sci.*, **3**, 874 (2014).
2. T.L. Wright, 5-Chloro-*s*-triazolo[4,3-a]pyridin-7-carboxylic acids, E.P. EP 0210648 B1 (1986).
3. P. Bourgeois, R. Cantegril, A. Chine, J. Gelin, J. Mortier and J. Moyroud, *Synth. Commun.*, **23**, 3195 (1993); <https://doi.org/10.1080/00397919308011179>.
4. J.A. Bristol and R.G. Lovey, [1,2,4]Triazolo[4,3-a]pyridines, U.S. Patent 4,358,453 (1982).
5. P.J. Nelson and K.T. Potts, *J. Org. Chem.*, **27**, 3243 (1962); <https://doi.org/10.1021/jo01056a061>.
6. K. Stach, M. Thiel, W. Voemel and F. Wiedemann, 5-Nitrofuryl-2-*s*-Triazolo-(4,3-a)pyridine Derivatives, U.S. Patent 3597423 (1971).
7. M.E.A. Zaki, O.A. Fathalla, S.A. Swelam and H.F. Aly, *Acta Pol. Pharm.*, **61**, 55 (2004).
8. J.M. Cic-Nunez, A.I. De Lucas Olivares, A.A. Trabanco-Suarez and G.J. MacDonald, 1,2,4-Triazolo[4,3-a]pyridine Derivatives and Their Use as Positive Allosteric Modulators of MGLUR2 Receptors, U.S. Patent 20120184527A1 (2012).
9. J.M. Cid-Nunez, D. Oehlich, A.A. Trabanco-Suarez, G.J. Tresadern, J.A.V. Ramiro and G.J. MacDonald, 1,2,3-Triazolo[4,3-a]pyridine Derivatives and Their use for the Treatment of Prevention of Neurological and Psychiatric Disorders, U.S. Patent 0184525A1 (2012).
10. J.F. Braganza, M.A. Letavic and K.F. McClure, Triazolo-pyridines as Antiinflammatory Compounds, WO 2004072072 A1 (2004).
11. M.A. Dombroski, M.A. Letavic and K.F. McClure, Di and Trifluoro-Triazolo-Pyridines Anti-inflammatory Compounds, WO 2004020440 A1 (2004).
12. M.A. Letavic, M.A. Dombroski, K.F. McClure and E.R. Laird, Novel Benzo-triazoles Antiinflammatory Compounds, U.S. Patent 2003/0078432 A1 (2003).
13. J. Aiguadé, C. Balagué, I. Carranco, F. Caturla, M. Domínguez, P. Eastwood, C. Esteve, J. González, W. Lumeras, A. Orellana, S. Preciado, R. Roca, L. Vidal and B. Vidal, *Bioorg. Med. Chem. Lett.*, **22**, 3431 (2012); <https://doi.org/10.1016/j.bmcl.2012.03.099>.
14. J.J. Li, J.J. Li, J. Li, A.K. Trehan, H.S. Wong, S. Krishnananthan, L.J. Kennedy, Q. Gao, A. Ng, J.A. Robl, B. Balasubramanian and B.-C. Chen, *Org. Lett.*, **10**, 2897 (2008); <https://doi.org/10.1021/ol8011748>.
15. J.Y. Roberge, G. Yu, A. Mikkilineni, X. Wu, Y. Zhu, R.M. Lawrence and W.R. Ewing, *ARKIVOC*, 132 (2007); <https://doi.org/10.3998/ark.5550190.0008.c10>.
16. I. Musie and B. Verèek, *Synth. Commun.*, **31**, 1511 (2001); <https://doi.org/10.1081/SCC-100104063>.
17. A. Reichelt, J.R. Falsey, R.M. Rzasa, O.R. Thiel, M.M. Achmatowicz, R.D. Larsen and D. Zhang, *Org. Lett.*, **12**, 792 (2010); <https://doi.org/10.1021/ol902868q>.
18. T.L. Wright, (Tetrazolyl) Thienopyridinones, U.S. Patent 4593099 A (1986).